Health AI Central
Peer-Reviewed Publication
Circulation2026September 22, 2026Journal Article

Real-World Experience With the Extravascular Implantable Cardioverter Defibrillator Through 1 Year: The Enlighten Post Approval Registry Study.

Lucas V A Boersma1,2, Anish Amin3, Francis Murgatroyd4, Maciej Sterliński5, Jens Brock Johansen6, Karim Saleh7, Pamela K Mason8, Jaime Casares9, Gregory Engel10, David Duncker11, Alexander Breitenstein12, Theodore Takata13, Laurence M Epstein14, Jurren M van Opstal15, Nicolas Clémenty16, Paul Friedman17, Oliver Monfredi8, Marianne Gwechenberger18, Nobuhiro Nishii19, Christopher Wiggenhorn20, Jeff D Lande20, Jennifer Lee20, Amy E Thompson20, Thomas R Holmes20, Ian Crozier21,
1Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands (L.V.A.B.).
2Amsterdam University Medical Center, Amsterdam, the Netherlands (L.V.A.B.).
3Riverside Methodist Hospital, Columbus, OH (A.A.).
4King's College Hospital, London, United Kingdom (F.M.).
5I Klinika Zaburzeń Rytmu Serca, Narodowy Instytut Kardiologii, Warszawa, Poland (M.S.).
6Odense University Hospital, Odense, Denmark (J.B.J.).
7Kepler University Hospital, Linz, Austria (K.S.).
8University of Virginia School of Medicine, Charlottesville, VA (P.K.M., O.M.).
9Hospital Universitario Reina Sofia, Cordoba, Spain (J.C.).
10Sutter Health, Redwood City, CA (G.E.).
11Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany (D.D.).
12University Heart Center, University Hospital Zurich, Zurich, Switzerland (A.B.).
13Texas Health Heart and Vascular Specialists, Fort Worth, TX (T.T.).
14Northwell Health, New Hyde Park, NY (L.M.E.).
15Medical Spectrum Twente, Enschede, the Netherlands (J.M.v.O.).
16Clinique du Millénaire, Montpellier, France (N.C.).
17Mayo Clinic, Rochester, MN (P.F.).
18Medical University of Vienna, Vienna, Austria (M.G.).
19Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan (N.N.).
20Medtronic Inc, Mounds View, MN (C.W., J.D.L., J.L., A.E.T., T.R.H.).
21Christchurch Hospital, Christchurch, New Zealand (I.C.).
PubMed DOI

Abstract

BACKGROUND: The extravascular implantable cardioverter defibrillator (EV-ICD) was developed to provide defibrillation and antitachycardia pacing therapy without the need for intravascular lead placement. Premarket clinical trials reported EV-ICD safety and efficacy through 3 years, but a real-world assessment of the Aurora EV-ICD system, which includes a novel sensing discriminator, is needed. The…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.